These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37455444)

  • 1. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colonoscopy findings after increasing two-stool faecal immunochemical test (FIT) cut-off: Cross-sectional analysis of the SCREESCO randomized trial.
    Westerberg M; Eriksson J; Metcalfe C; Löwbeer C; Ekbom A; Steele R; Holmberg L; Forsberg A
    J Intern Med; 2024 Aug; 296(2):187-199. PubMed ID: 38845164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain).
    Portillo I; Arana-Arri E; Idigoras I; Bilbao I; Martínez-Indart L; Bujanda L; Gutierrez-Ibarluzea I
    World J Gastroenterol; 2017 Apr; 23(15):2731-2742. PubMed ID: 28487610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program.
    Wisse PHA; de Boer SY; Oudkerk Pool M; Terhaar Sive Droste JS; Verveer C; Meijer GA; Dekker E; Spaander MCW
    Endoscopy; 2024 May; 56(5):364-372. PubMed ID: 38101446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal Cancer Screening Pilot Project in Tehran-Iran, a Feasibility Study.
    Salimzadeh H; Sauvaget C; Delavari A; Sadeghi A; Amani M; Salimzadeh S; Karimi A; Ghanbari Motlagh A; Lucas E; Basu P; Malekzadeh R
    Arch Iran Med; 2023 Mar; 26(3):138-146. PubMed ID: 37543936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer population screening programs worldwide in 2016: An update.
    Navarro M; Nicolas A; Ferrandez A; Lanas A
    World J Gastroenterol; 2017 May; 23(20):3632-3642. PubMed ID: 28611516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.
    Canévet M; Pruvost-Couvreur M; Morvan M; Badic B; Brousse-Potocki J; Kermarrec T; Bouzeloc S; Nousbaum JB; Robaszkiewicz M; Reboux N; Quénéhervé L
    Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102093. PubMed ID: 36764389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the "Burgenland PREvention trial of colorectal cancer Disease with ImmunologiCal Testing" (B-PREDICT)-a population-based colorectal cancer screening program.
    Brezina S; Leeb G; Baierl A; Gräf E; Hackl M; Hofer P; Lang H; Klein M; Mach K; Schwarzer R; Wlassits W; Püspök A; Gsur A
    BMC Gastroenterol; 2024 Apr; 24(1):149. PubMed ID: 38689217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal cut-off value for detecting colorectal cancer with fecal immunochemical tests according to age and sex.
    Vanaclocha-Espi M; Ibáñez J; Molina-Barceló A; Valverde-Roig MJ; Nolasco A; Pérez-Riquelme F; de la Vega M; Portillo I; Salas D
    PLoS One; 2021; 16(7):e0254021. PubMed ID: 34270590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer screening with fecal immunochemical testing or primary colonoscopy: inequities in diagnostic yield.
    Bonander C; Westerberg M; Chauca Strand G; Forsberg A; Strömberg U
    JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38830030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Essink-Bot ML; Spaander MC; Dekker E
    Br J Cancer; 2017 Jan; 116(1):44-49. PubMed ID: 27923037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 19. Positive impact of a faecal-based screening programme on colorectal cancer mortality risk.
    Ibáñez-Sanz G; Milà N; Vidal C; Rocamora J; Moreno V; Sanz-Pamplona R; Garcia M;
    PLoS One; 2021; 16(6):e0253369. PubMed ID: 34191813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.